One of the reasons I liked this stock was the market diversity...

One of the reasons I liked this stock was the market diversity of their products, spreading the risk. But the weakest link in their pipeline is clearly the final selling part.

There is scant evidence of there marketing campaigns other than having stalls at international trade conventions. They need advertising in medical, veterinary and trade journals, social media, direct marketing, and so on.

Veterinary, medical, military, law enforcement, elite sports, professional sports, so on and so on ... Many, markets markets, but where's the marketing?

How does a CEO on this kind of pay, that's supposed to be an expert in commercialising, not see that the marketing and sales need to be the focus. From sales they can fund r&d on the other products without stealing more money from shareholders.

And of course, they should take a pay cut until they show results in the bottom line.